Advertisement
Singapore markets close in 4 hours 23 minutes
  • Straits Times Index

    3,294.90
    +22.18 (+0.68%)
     
  • Nikkei

    38,356.71
    +804.55 (+2.14%)
     
  • Hang Seng

    17,110.21
    +281.28 (+1.67%)
     
  • FTSE 100

    8,044.81
    +20.94 (+0.26%)
     
  • Bitcoin USD

    66,690.70
    +281.14 (+0.42%)
     
  • CMC Crypto 200

    1,436.03
    +21.27 (+1.50%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • Dow

    38,503.69
    +263.71 (+0.69%)
     
  • Nasdaq

    15,696.64
    +245.33 (+1.59%)
     
  • Gold

    2,341.10
    -1.00 (-0.04%)
     
  • Crude Oil

    83.42
    +0.06 (+0.07%)
     
  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     
  • FTSE Bursa Malaysia

    1,567.97
    +6.33 (+0.41%)
     
  • Jakarta Composite Index

    7,169.11
    +58.30 (+0.82%)
     
  • PSE Index

    6,572.32
    +65.52 (+1.01%)
     

Sanofi poaches former PSA finance boss Chasseloup de Chatillon

FILE PHOTO: French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris, France, March 8, 2016. REUTERS/Philippe Wojazer/File Photo (Reuters)

PARIS (Reuters) - French drugmaker Sanofi <SASY.PA> announced it had hired Jean-Baptiste Chasseloup de Chatillon, the former chief financial officer at carmaker and Peugeot-manufacturer PSA <PEUP.PA> who had helped oversee a revival in PSA's fortunes.

Sanofi said Chasseloup de Chatillon would become its executive vice-president and chief financial officer, with his position taking effect on October 1, replacing Jerome Contamine who will be retiring.

"Jean-Baptiste is an experienced CFO who has been part of the impressive turnaround of PSA Group," said Sanofi chief executive Olivier Brandicourt in a statement.

PSA had posted a series of record earnings results over the last two years, having rebounded from a 2012 brush with bankruptcy, and Chasseloup de Chatillon had been a member of Peugeot's managing board since 2012.

ADVERTISEMENT

Chasseloup de Chatillon will arrive at Sanofi at a time of blockbuster deals within the global healthcare industry.

Sanofi has already struck two major takeover deals this year, buying haemophilia specialist Bioverativ for $11.6 billion and acquiring Ablynx, which is developing a prized experimental drug for a rare blood disorder, for 3.9 billion euros (3.40 billion pounds).

The transactions marked a return to successful deal-making for Sanofi after failures to land major takeovers since 2011, when it bought U.S biotech company Genzyme for around $20 billion, although some investors have questioned the costs.

(Reporting by Sudip Kar-Gupta and Gilles Guillaume; Editing by Bate Felix)